Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.82 times its estimated earnings per share for the ongoing year.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
Ratings chart
Sector Medical Equipment
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES-9.15%139 153
MASIMO CORPORATION13.73%9 670
NOVOCURE LIMITED-20.09%6 979
ASAHI INTECC CO., LTD.-0.22%6 493
JIANGSU YUYUE MEDICAL EQUIP..-4.68%5 383
GETINGE3.10%5 341
SHOCKWAVE MEDICAL, INC.-24.45%1 142
TACTILE SYSTEMS TECHNOLOGY,..-40.51%784
SI-BONE, INC.-44.42%351
SEMLER SCIENTIFIC, INC.-22.92%242
I-SENS INC--.--%223
BIOCARTIS GROUP NV-39.60%218
DAIKEN MEDICAL CO., LTD.0.44%181
MISONIX, INC.-49.38%167
APOLLO ENDOSURGERY, INC.-32.63%45
ELECTROCORE, INC.-40.25%36
More Results
Financials (USD)
Sales 2020 33 177 M
EBIT 2020 7 149 M
Net income 2020 4 206 M
Debt 2020 10 625 M
Yield 2020 1,80%
P/E ratio 2020 32,6x
P/E ratio 2021 26,3x
EV / Sales2020 4,51x
EV / Sales2021 4,03x
Capitalization 139 B
Upcoming event on ABBOTT LABORATORIES
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes